Impact of Hepatitis B Virus (HBV) Infection on Efficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (Pembro) Plus Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC)
| dc.contributor.author | Yau, T. | |
| dc.contributor.author | Chan, S.L. | |
| dc.contributor.author | Kelley, R.K. | |
| dc.contributor.author | Finn, R.S. | |
| dc.contributor.author | Yoo, C. | |
| dc.contributor.author | Furuse, J. | |
| dc.contributor.author | Qin, S. | |
| dc.date.accessioned | 2024-08-25T15:13:17Z | |
| dc.date.available | 2024-08-25T15:13:17Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Background: In KEYNOTE-966, pembro + gem/cis significantly increased overall survival compared with placebo + gem/cis alone as first-line therapy for patients (pts) with advanced BTC (hazard ratio [HR] = 0.83, 95% confidence interval [CI] 0.72-0.95; P = 0.0034). Chronic HBV infection is a known risk factor for BTC and may impact the effectiveness of immunotherapy in patients with BTC. An exploratory analysis showed low incidence of HBV reactivation and no cases of HBV-associated hepatitis in HBV-positive pts from KEYNOTE-966. Here, we present a post hoc analysis from KEYNOTE-966 to assess whether patient HBV infection status is associated with differences in efficacy and safety outcomes. Methods: Pts were randomized 1:1 to pembro 200 mg IV or placebo IV Q3W for #35 cycles plus gem 1000 mg/m2 IV until disease progression and cis 25 mg/m2 IV for #8 cycles. HBV status was determined by anti-HBc (total and IgM), HBV DNA, and HBsAg. Pts with chronic HBV infection (HBsAg positive and/or detectable HBV DNA) and clinically resolved HBV infection (HBsAg negative and anti-HBc positive, and undetectable HBV DNA) at baseline were eligible and comprised the HBV-positive subgroup. Pts with chronic HBV infection needed to have begun antiviral therapy $4 weeks before, and HBV DNA,100 IU/mL prior to, starting study treatment. The data cutoff date for this analysis was November 14, 2023. Results: 1069 pts were enrolled in KEYNOTE-966. 329 (30.8%) were HBV positive (164 from pembro arm vs 165 from placebo arm) and 732 (68.5%) were HBV negative (366 from pembro arm vs 366 placebo arm); 8 had unknown HBV status at baseline. More pts in the HBV-positive subgroup were male (60.8% vs 47.4% in the HBV-negative group), $65 years old (53.2% vs 44.5%), and from Asia (76.9% vs 31.8%). In the HBV-positive subgroup, median OS was 12.3 mo (95% CI 9.5-14.5) for the pembro arm vs 10.9 mo (95% CI 9.7-13.2) for the placebo arm (HR = 0.87, 95% CI 0.69-1.10). For the HBV-negative subgroup, median OS was 12.8 mo (95% CI 11.4-13.9) for the pembro arm vs 10.7 mo (95% CI 9.4-11.7) for the placebo arm (HR = 0.85, 95% CI 0.73-0.99). Grade 3-5 treatment-related AE rates in the pembro arm vs the placebo arm were 69% vs 73% of pts in the HBV-positive subgroup and 72% vs 68% in the HBV-negative subgroup, respectively. Rates of discontinuation of any drug due to a treatment-related AE in the pembro arm vs the placebo arm were 14% vs 15% in the HBV-positive subgroup and 22% vs 16% in the HBV-negative subgroup. Conclusions: Efficacy and safety outcomes remained consistent between HBV-positive and HBV-negative subgroups from KEYNOTE-966. These data further support pembro + gem/cis as first-line therapy for advanced BTC regardless of HBV infection status. Clinical trial information: NCT04246177. Research Sponsor: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. © 2024 All rights reserved. | en_US |
| dc.identifier.doi | 10.1200/JCO.2024.42.16_suppl.4097 | |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.issn | 1527-7755 | |
| dc.identifier.scopus | 2-s2.0-105023423392 | |
| dc.identifier.uri | https://doi.org/10.1200/JCO.2024.42.16_suppl.4097 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/5469 | |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott Williams and Wilkins | en_US |
| dc.relation.ispartof | Journal of Clinical Oncology | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Impact of Hepatitis B Virus (HBV) Infection on Efficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (Pembro) Plus Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC) | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.scopusid | 23391533100 | |
| gdc.author.scopusid | 34973871600 | |
| gdc.author.scopusid | 17635112900 | |
| gdc.author.scopusid | 35181198600 | |
| gdc.author.scopusid | 22954694200 | |
| gdc.author.scopusid | 59658085700 | |
| gdc.author.scopusid | 7201933229 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | true | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Yau] Thomas Chung Cheung, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Chan] Stephen Lam, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Kelley] Robin Kate, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Finn] Richard S., The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Yoo] Changhoon, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Furuse] Junji, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Ren] Zhenggang, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Klu¨mpen] Heinz Josef, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Ozaka] Masato, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Pelzer] Uwe, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Arslan] Çaǧatay, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Park] Joon-oh, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Edeline] Julien, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Valle] Juan W., The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Ueno] Makoto, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Vogel] Arndt, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Starkopf] Liis, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Malhotra] Usha, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Siegel] Abby B., The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China; [Qin] Shukui, The University of Hong Kong, Hong Kong, Hong Kong, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong, University of California, San Francisco, San Francisco, CA, United States, University of California, Los Angeles, Los Angeles, CA, United States, Department of Oncology, Asan Medical Center, Seoul, Seoul, South Korea, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan, Department of Hepatic Oncology, Fudan University, Shanghai, China, Department of Medical Oncology, Universiteit van Amsterdam, Amsterdam, Noord-Holland, Netherlands, Cancer Institute Hospital of Japan Foundation for Cancer Research, Tokyo, Tokyo, Japan, Charité – Universitätsmedizin Berlin, Berlin, Berlin, Germany, Izmir Ekonomi Üniversitesi, Izmir, Turkey, Samsung Medical Center, Sungkyunkwan university, Seoul, South Korea, Eugène Marquis Center, Rennes, France, The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom, Hannover Medical School, Hannover, Niedersachsen, Germany, Merck & Co., Inc., Rahway, NJ, United States, The 81 Hospital of People's Liberation Army of China, Nanjing, Jiangsu, China | en_US |
| gdc.description.issue | 16 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | N/A | |
| gdc.description.volume | 42 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded - Conference Proceedings Citation Index - Science | |
| gdc.description.wosquality | N/A | |
| gdc.identifier.openalex | W4399736669 | |
| gdc.identifier.wos | WOS:001275557401069 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 0.0 | |
| gdc.oaire.influence | 2.5349236E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.popularity | 2.4744335E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 0.6057 | |
| gdc.openalex.normalizedpercentile | 0.68 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.scopuscites | 0 | |
| gdc.scopus.citedcount | 0 | |
| gdc.wos.citedcount | 0 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 |